Explore more press releases
Topics
Period
recent search
Showing: 1 – 05 of 228 Press Releases
19 December 2025
19 December 2025
Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP)
PARIS, FRANCE, 19 December 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the pivotal Phase II FALKON trial did not meet its primary endpoint of reducing new heterotopic ossification (HO) in adults and children living with fibrodysplasia ossificans progressiva…
15 December 2025
15 December 2025
Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline
PARIS, FRANCE, 15 December 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced it has completed the acquisition of ImCheck Therapeutics, a private French biotechnology company pioneering next-generation immuno-oncology therapies.
01 December 2025
01 December 2025
Ipsen mourns the passing of Henri Beaufour, a founding family Board member
PARIS, FRANCE, 1 DECEMBER 2025 – It is with great sadness that Ipsen (Euronext: IPN; ADR: IPSEY) today announces that Henri Beaufour, Ipsen Board Member and a representative of the founding family, passed away on Friday, 28 November 2025.
07 November 2025
07 November 2025
22 October 2025
22 October 2025
Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance
PARIS, FRANCE, 22 October 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the year to date and the third quarter of 2025.
Your dedicated contacts
-
Media Relations
-
